CiToxLAB increases capabilities in reprotoxicology and juvenile studies
Appoints Paul Barrow as director of scientific projects and client consulting
Barrow has more than 30 years’ experience in preclinical safety testing, gained through working for the pharmaceutical industry and CROs in France, the UK and Italy.
Most recently Barrow was a director of toxicology at Ricerca Biosciences. In more than 10 years at Ricerca, he collaborated with more than 100 clients from the pharmaceutical, biotech, chemical and food industries to devise and execute non-clinical regulatory submission packages and to address pre- and post-marketing safety issues.
Barrow is a member of the Society of Toxicology, the Teratology Society, the European Teratology Society, Eurotox and is a European Registered Toxicologist.
You may also like
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development
AlzeCure Pharma publishes response letter clarifying Alzstatin’s distinct mechanism in Alzheimer’s treatment
AlzeCure Pharma and leading academic collaborators have published a response in JPET addressing recent commentary on Alzstatin’s γ-secretase modulation data, reaffirming the promise of lead candidate ACD680 in Alzheimer’s therapy